The “ColoSense” multitarget stool RNA test has demonstrated superior sensitivity and specificity for detecting colorectal cancer and advanced adenomas compared to traditional colonoscopy. Developed by Dr. Erica Barnell of Washington University School of Medicine and founder of Geneoscopy Inc, the test was evaluated in the CRC-PREVENT study, a cross-sectional prospective pivotal trial.
The study used a decentralized recruitment model through social media, targeting average-risk Americans over the age of 45 for colorectal cancer screening. The ColoSense test showed a 94.4% sensitivity for colorectal cancer, 46% sensitivity for advanced adenomas, and 88% specificity for identifying no findings during a colonoscopy. The test’s scalability and effectiveness, particularly in the younger age population (ages 45 to 50), make it a promising noninvasive screening option for colorectal cancer.